Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | YWHAG | P61981 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29960223 | 0.91 | TGFBR1 (0.56) | TGFBR1MAPK14LMNAATMAURKA | |
| SCHEMBL23409854 | 0.91 | TGFBR1 (0.56) | TGFBR1MAPK14LMNAATMAURKA | |
| SCHEMBL28822081 | 0.90 | TGFBR1 (0.68) | TGFBR1MAPK14 | |
| SCHEMBL28822096 | 0.89 | TGFBR1 (0.56) | TGFBR1MAPK14AURKAAURKBTHRB | |
| SCHEMBL28822077 | 0.88 | TGFBR1 (0.59) | TGFBR1MAPK14LMNA | |
| SCHEMBL28822071 | 0.88 | TGFBR1 (0.69) | TGFBR1MAPK14LMNAAURKAAURKB | |
| SCHEMBL29959696 | 0.88 | TGFBR1 (0.59) | TGFBR1MAPK14LMNA | |
| SCHEMBL23409906 | 0.88 | TGFBR1 (0.59) | TGFBR1MAPK14LMNA | |
| SCHEMBL23409664 | 0.85 | TGFBR1 (0.59) | TGFBR1MAPK14LMNAAURKAAURKB | |
| SCHEMBL23409951 | 0.85 | TGFBR1 (0.59) | TGFBR1MAPK14LMNAAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297186-B2 | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 | Agomab Spain, S.L.U. (ES) | 2025-05-13 | — | — | US | claimed |
| CN-114787145-B | Benzamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors | 阿戈麦布西班牙股份有限公司 | 2024-03-26 | — | — | CN | claimed |
| EP-4065572-A1 | BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 | Origo Biopharma, S.L. (ES) | 2022-10-05 | — | — | EP | claimed |
| CN-114787145-A | Benzamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors | 奥里戈生物制药有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-114787145-B | Benzamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors | 阿戈麦布西班牙股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-4065572-A1 | BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 | Origo Biopharma, S.L. (ES) | 2022-10-05 | — | — | EP | disclosed |
| CN-114787145-A | Benzamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors | 奥里戈生物制药有限公司 | 2022-07-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297186-B2 | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 | TGFBR2, TGFBR1, ACVR1 | TGFBR1 2/4885MAPK14 1610/4885LMNA 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.